<html>
<head>
<META http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>NCT00144300 on 2008_10_01: ClinicalTrials.gov Archive</title>
<link rel="stylesheet" href="/archive/history.css">
<link rel="stylesheet" href="/archive/received.css">
</head>
<body class="received">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="navLinks" class="navLinks"><a href="/archive/NCT00144300">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT00144300">&#8593; Current version of this study</a></div><h1>View of NCT00144300 on
  2008_10_01</h1>
<table class="info">
<tr>
<th nowrap>ClinicalTrials Identifier:</th><td>NCT00144300</td>
</tr>
<tr>
<th>Updated:</th><td>2008_10_01</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Descriptive Information</h2>
</th>
</tr>
<tr>
<th>Brief title</th><td>
<p>Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early Parkinson Disease (PD) Patients</p>
</td>
</tr>
<tr>
<th>Official title</th><td>
<p>A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients</p>
</td>
</tr>
<tr>
<th>Brief summary</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>The objectives of this trial conducted in early PD patients are to determine the efficacy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(as measured by the change from baseline to the end of the maintenance phase in the total score for UPDRS Parts II and III combined), safety, and tolerability of Pramipexole ER &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(in daily doses from 0.375mg to 4.5mg q.d.) in comparison to placebo, and to test for non-inferiority between the two formulations (ER and IR) of pramipexole.<br>In addition, the efficacy of Pramipexole IR will be compared to placebo, for assay sensitivity</p>
</td>
</tr>
<tr>
<th>Detailed description</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p></p>
</td>
</tr>
<tr>
<th>Phase</th><td>Phase 4</td>
</tr>
<tr>
<th>Study type</th><td>Interventional</td>
</tr>
<tr>
<th>Study design</th><td>Treatment</td>
</tr>
<tr>
<th>Study design</th><td>Parallel Assignment</td>
</tr>
<tr>
<th>Study design</th><td>Safety/Efficacy Study</td>
</tr>
<tr>
<th>Primary outcome</th><td>Measure: The primary efficacy endpoint of the trial is the change from baseline to end of the maintenance period in UPDRS parts II+III score.<br>Time Frame: 33 weeks</td>
</tr>
<tr>
<th>Secondary outcome</th><td>Measure: Responder rate for Clinical Global Impression of Improvement 
Responder rate for Patient Global Impression of Improvement 
UPDRS I, II and III scores separately<br>Time Frame: 33 weeks</td>
</tr>
<tr>
<th>Condition</th><td>
         Parkinson Disease
      </td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: pramipexole IR</div>
<p></p>
</td>
</tr>
<tr>
<th>Intervention</th><td>
<div>Drug: ropinirole</div>
<p></p>
</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Recruitment Information</h2>
</th>
</tr>
<tr>
<th>Status</th><td>Recruiting</td>
</tr>
<tr>
<th>Start date</th><td>
         2005-01
      </td>
</tr>
<tr>
<th>Primary completion date</th><td>
         2010-07
      
      (Anticipated)
  </td>
</tr>
<tr>
<th>Criteria</th>
</tr>
<tr>
<td colspan="2" class="bigdent">
<p>Inclusion Criteria:<br>1.	Male or female patient with idiopathic Parkinsons disease (PD) confirmed by at least two of the following signs: resting tremor, bradykinesia, rigidity.<br>2.	Parkinsons disease diagnosed within 5 years.<br>3.	Patients 30 years of age or older at the time of diagnosis.<br>4.	Modified Hoehn and Yahr stage of 1 to 3.<br>5.	Patients requiring additional therapy/ introduction of therapy (for de novo patients) to treat their parkinsonian symptoms at the time of enrolment (screening visit, V1) according to the investigators judgement.<br>
<br>
<br>Exclusion Criteria:<br>1.	Atypical parkinsonian syndromes due to drugs (e.g., metoclopramide, flunarizine), metabolic disorders (e.g., Wilson's disease), encephalitis or degenerative diseases (e.g., progressive supranuclear palsy).<br>2.	Dementia, as defined by a Mini-Mental State Exam score &lt; 24 at screening visit<br>3.	Any psychiatric disorder according to DSM-IV<br>4.	History of psychosis<br>5.	Clinically significant electrocardiogram (ECG) abnormalities at screening visit<br>6.	Clinically significant hypotension<br>7.	Malignant melanoma or history of previously treated malignant melanoma<br>8.	Any other clinically significant disease, whether treated or not, that could put the patient at risk or could prevent compliance or completion of the study<br>9.	Pregnancy<br>10.	Sexually active female of childbearing potential not using a medically approved method of birth control<br>11.	Serum levels of AST (SGOT), ALT (SGPT), alkaline phosphatases or bilirubin &gt; 2 ULN<br>12.	Patients with a creatinine clearance &lt; 50 mL/min<br>13.	Any dopamine agonist (including pramipexole) within 4 weeks prior to baseline visit, or L-Dopa within 8 weeks prior to baseline visit.<br>14.	Total cumulative duration of prior exposure to Levodopa of more than 3 months.<br>15.	Any medication (including intra-muscular formulations) with central dopaminergic antagonist activity within 4 weeks prior to the baseline visit<br>16.	Any of the following drugs within 4 weeks prior to the baseline visit: methylphenidate, cinnarizine, amphetamines.<br>17.	Flunarizine within 3 months prior to baseline visit<br>18.	Known hypersensitivity to Pramipexole or its excipients<br>19.	Drug abuse (including alcohol), according to Investigators judgement, within 2 years prior to screening.<br>20.	Participation in other investigational drug studies or use of other investigational drugs within one month or five times the half-life of the investigational drug</p>
</td>
</tr>
<tr>
<th>Gender</th><td>
            Both
         </td>
</tr>
<tr>
<th>Minimum age</th><td>30 Years</td>
</tr>
<tr>
<th>Healthy volunteers</th><td>No</td>
</tr>
<tr>
<th class="section" colspan="2">
<h2>Administrative Data</h2>
</th>
</tr>
<tr>
<th>Organization name</th><td>Boehringer Ingelheim Pharmaceuticals</td>
</tr>
<tr>
<th>Organization study ID</th><td>248.538</td>
</tr>
<tr>
<th>Secondary ID</th><td>
            Eudract No 2007-000073-39
         </td>
</tr>
<tr>
<th>Sponsor</th><td>
               Boehringer Ingelheim Pharmaceuticals
            </td>
</tr>
<tr>
<th>Health Authority</th><td>
               United States: Food and Drug Administration
         </td>
</tr>
</table><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div></body>
</html>
